NEW HOPE, Pa.--(BUSINESS WIRE)--Protalex, Inc. (OTCBB:PRTX) announced today that Chris Yatko, Research Scientist at Protalex will present data from the Company’s in vitro study of the effect of the Company’s lead compound, PRTX-100, on phagocytosis of platelets for the potential treatment of patients with Idiopathic Thrombocytopenic Purpura, a rare blood clotting disorder. The data will be presented at the American Society of Hematology 48th Annual Meeting and Exposition, to be held December 9-12, 2006 at the Orange County Convention Center in Orlando, FL.
